Trial Profile

Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BGC-101-BioGenCell (Primary)
Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms EnEPC-CLI
Sponsors BioGenCell

31 Aug 2026 Planned number of patients changed from 40 to 50.
06 Jun 2025 Planned number of patients changed from 50 to 40.
19 Dec 2024 Status changed from recruiting to active, no longer recruiting, according to a BioGenCell media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com